CHM chimeric therapeutics limited

News: CHM Chimeric Therapeutics Says Execution Of Clinical Study Agreement With University Of Texas...

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Sept 13 (Reuters) - Chimeric Therapeutics Ltd (CHM) :

    • EXECUTION OF A CLINICAL STUDY AGREEMENT WITH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
    • STUDY, WHICH HAS RECEIVED IND CLEARANCE BY FDA AND IS EXPECTED TO OPEN TO ENROLLMENT AT MD ANDERSON BY YEAR END 2023
    • CLINICAL STUDY AGREEMENT TO SUPPORT "ADVENT-AML" PHASE 1B STUDY
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $28.14K 7.037M

Buyers (Bids)

No. Vol. Price($)
1 243067 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 14771167 22
View Market Depth
Last trade - 15.39pm 20/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.